263 related articles for article (PubMed ID: 25200860)
1. Profiling the tyrosine phosphoproteome of different mouse mammary tumour models reveals distinct, model-specific signalling networks and conserved oncogenic pathways.
Ali NA; Wu J; Hochgräfe F; Chan H; Nair R; Ye S; Zhang L; Lyons RJ; Pinese M; Lee HC; Armstrong N; Ormandy CJ; Clark SJ; Swarbrick A; Daly RJ
Breast Cancer Res; 2014 Sep; 16(5):437. PubMed ID: 25200860
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.
Hochgräfe F; Zhang L; O'Toole SA; Browne BC; Pinese M; Porta Cubas A; Lehrbach GM; Croucher DR; Rickwood D; Boulghourjian A; Shearer R; Nair R; Swarbrick A; Faratian D; Mullen P; Harrison DJ; Biankin AV; Sutherland RL; Raftery MJ; Daly RJ
Cancer Res; 2010 Nov; 70(22):9391-401. PubMed ID: 20861192
[TBL] [Abstract][Full Text] [Related]
3. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
[TBL] [Abstract][Full Text] [Related]
4. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.
Cicchini M; Chakrabarti R; Kongara S; Price S; Nahar R; Lozy F; Zhong H; Vazquez A; Kang Y; Karantza V
Autophagy; 2014; 10(11):2036-52. PubMed ID: 25483966
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine kinase signalling in breast cancer: tyrosine kinase-mediated signal transduction in transgenic mouse models of human breast cancer.
Andrechek ER; Muller WJ
Breast Cancer Res; 2000; 2(3):211-6. PubMed ID: 11250712
[TBL] [Abstract][Full Text] [Related]
6. Progression of familial adenomatous polyposis (FAP) colonic cells after transfer of the src or polyoma middle T oncogenes: cooperation between src and HGF/Met in invasion.
Empereur S; Djelloul S; Di Gioia Y; Bruyneel E; Mareel M; Van Hengel J; Van Roy F; Comoglio P; Courtneidge S; Paraskeva C; Chastre E; Gespach C
Br J Cancer; 1997; 75(2):241-50. PubMed ID: 9010033
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer.
Schwab LP; Peacock DL; Majumdar D; Ingels JF; Jensen LC; Smith KD; Cushing RC; Seagroves TN
Breast Cancer Res; 2012 Jan; 14(1):R6. PubMed ID: 22225988
[TBL] [Abstract][Full Text] [Related]
8. Quantitative phospho-proteomic profiling of hepatocyte growth factor (HGF)-MET signaling in colorectal cancer.
Organ SL; Tong J; Taylor P; St-Germain JR; Navab R; Moran MF; Tsao MS
J Proteome Res; 2011 Jul; 10(7):3200-11. PubMed ID: 21609022
[TBL] [Abstract][Full Text] [Related]
9. Targeting Met and Notch in the Lfng-deficient, Met-amplified triple-negative breast cancer.
Zhang S; Chung WC; Miele L; Xu K
Cancer Biol Ther; 2014 May; 15(5):633-42. PubMed ID: 24556651
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
11. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.
Bachleitner-Hofmann T; Sun MY; Chen CT; Tang L; Song L; Zeng Z; Shah M; Christensen JG; Rosen N; Solit DB; Weiser MR
Mol Cancer Ther; 2008 Nov; 7(11):3499-508. PubMed ID: 18974395
[TBL] [Abstract][Full Text] [Related]
12. SK4 channels modulate Ca
Steudel FA; Mohr CJ; Stegen B; Nguyen HY; Barnert A; Steinle M; Beer-Hammer S; Koch P; Lo WY; Schroth W; Hoppe R; Brauch H; Ruth P; Huber SM; Lukowski R
Mol Oncol; 2017 Sep; 11(9):1172-1188. PubMed ID: 28557306
[TBL] [Abstract][Full Text] [Related]
13. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.
Brevet M; Shimizu S; Bott MJ; Shukla N; Zhou Q; Olshen AB; Rusch V; Ladanyi M
J Thorac Oncol; 2011 May; 6(5):864-74. PubMed ID: 21774103
[TBL] [Abstract][Full Text] [Related]
14. Critical roles of DMP1 in human epidermal growth factor receptor 2/neu-Arf-p53 signaling and breast cancer development.
Taneja P; Maglic D; Kai F; Sugiyama T; Kendig RD; Frazier DP; Willingham MC; Inoue K
Cancer Res; 2010 Nov; 70(22):9084-94. PubMed ID: 21062982
[TBL] [Abstract][Full Text] [Related]
15. Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells.
Matsubara D; Ishikawa S; Oguni S; Aburatani H; Fukayama M; Niki T
J Thorac Oncol; 2010 Sep; 5(9):1317-24. PubMed ID: 20736805
[TBL] [Abstract][Full Text] [Related]
16. Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice.
Burga LN; Hu H; Juvekar A; Tung NM; Troyan SL; Hofstatter EW; Wulf GM
Breast Cancer Res; 2011 Mar; 13(2):R30. PubMed ID: 21396117
[TBL] [Abstract][Full Text] [Related]
17. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.
Yoshida T; Zhang G; Smith MA; Lopez AS; Bai Y; Li J; Fang B; Koomen J; Rawal B; Fisher KJ; Chen YA; Kitano M; Morita Y; Yamaguchi H; Shibata K; Okabe T; Okamoto I; Nakagawa K; Haura EB
Clin Cancer Res; 2014 Aug; 20(15):4059-4074. PubMed ID: 24919575
[TBL] [Abstract][Full Text] [Related]
18. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
[TBL] [Abstract][Full Text] [Related]
19. Reproductive history determines Erbb2 locus amplification, WNT signalling and tumour phenotype in a murine breast cancer model.
Ordonez LD; Melchor L; Greenow KR; Kendrick H; Tornillo G; Bradford J; Giles P; Smalley MJ
Dis Model Mech; 2021 May; 14(5):. PubMed ID: 34003256
[TBL] [Abstract][Full Text] [Related]
20. Activation of Src family kinases in Neu-induced mammary tumors correlates with their association with distinct sets of tyrosine phosphorylated proteins in vivo.
Muthuswamy SK; Muller WJ
Oncogene; 1995 Nov; 11(9):1801-10. PubMed ID: 7478608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
